In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, people who had been taking weekly semaglutide 2.4 mg (Wegovy) along with a lifestyle intervention regained two-thirds of the weight they had lost a year after coming off the drug.

New research suggests GLP-1 medications like Ozempic may help reduce several health risks in addition to treating type 2 diabetes and obesity.